(3-benzyl-1H-pyrazol-5-yl)(4-hydroxypiperidin-1-yl)methanone

ID: ALA5284999

Max Phase: Preclinical

Molecular Formula: C16H19N3O2

Molecular Weight: 285.35

Names and Identifiers

Canonical SMILES:  O=C(c1cc(Cc2ccccc2)n[nH]1)N1CCC(O)CC1

Standard InChI:  InChI=1S/C16H19N3O2/c20-14-6-8-19(9-7-14)16(21)15-11-13(17-18-15)10-12-4-2-1-3-5-12/h1-5,11,14,20H,6-10H2,(H,17,18)

Standard InChI Key:  ZVNMAPUHGLZWMC-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 21 23  0  0  0  0  0  0  0  0999 V2000
    1.6687   -0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0812    0.3572    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9062    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3186   -0.3571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9061   -1.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0812   -1.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3186   -1.7860    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.6687    1.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0812    1.7860    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.8438    1.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4312    0.3570    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3757    0.5286    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4619    1.3492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2916    1.6847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1768    1.7619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8916    1.3492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8916    0.5237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6020    0.1118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3186    0.5200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3186    1.3488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6038    1.7612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  3  1  0
  5  4  1  0
  1  6  1  0
  6  5  1  0
  5  7  1  0
  8  2  1  0
  8  9  2  0
 10  8  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 14 10  2  0
 14 13  1  0
 15 13  1  0
 16 15  1  0
 17 16  2  0
 18 17  1  0
 19 18  2  0
 20 19  1  0
 16 21  1  0
 21 20  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA5284999

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 285.35

Molecular Weight (Monoisotopic): 285.1477

AlogP: 1.60

#Rotatable Bonds: 3

Polar Surface Area: 69.22

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.42

CX Basic pKa: 2.15

CX LogP: 0.78

CX LogD: 0.78

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.90

Np Likeness Score: -1.09

References

1. Jo M, Koizumi K, Suzuki M, Kanayama D, Watanabe Y, Gouda H, Mori H, Mizuguchi M, Obita T, Nabeshima Y, Toyooka N, Okada T..  (2023)  Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.,  87  [PMID:37011768] [10.1016/j.bmcl.2023.129266]

Source

Source(1):

• Scientific Literature